038290.KQ Macrogen Inc
- Market cap
- KRW 118B
- P/E
- -
- P/B
- 0.76x
- ROE
- 5.7%
- Dividend yield
- 2.76%
- Fundamental score
- 2.5/5
Ratios use the latest price and the current fiscal year annualized from 2 quarters up to Jun 2026.
Is 038290.KQ undervalued?
Graham numberThe Graham number of Macrogen Inc cannot be estimated reliably (it needs positive earnings and book value).
Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?
Macrogen Inc fundamental analysis
12 of 22 checks passedROE 0/2
Low return on equity (5.7%), below 10%.
ROA 0/1
Return on assets (2.4%) is below the industry median (2.4%).
Profit Consistency 0/2
Not profitable for at least 3 consecutive years.
Earnings Growth 5Y 0/1
Earnings per share did not grow over the past 5 years.
Earnings Acceleration 1/1
Last year's EPS growth (126.7%) is above the 5-year average (-54.0% a year).
Earnings Growth vs Industry 1/1
Last year's EPS growth (126.7%) is above the industry median (54.3%).
Revenue Growth 2/2
Revenue grew 12.1% a year over the past 3 years.
Short-term Liquidity 0/1
Current assets do not cover short-term liabilities.
Long-term Liabilities 1/1
Current assets cover long-term liabilities.
Debt to Equity 2/2
Low debt to equity (10.2%), 40% or less.
Debt Trend 1/1
Debt to equity has not risen over the past 5 years.
Debt Coverage 1/1
Operating cash flow covers 20% of total debt.
Interest Coverage 1/1
No interest expense reported.
PE vs Market 0/1
PE is negative or not available.
PE vs Industry 0/1
PE is negative or not available.
PBV 1/1
Price to book (0.8x) is below the industry median (1.8x).
Graham Number 0/1
Graham number needs positive earnings and book value.
PEG 0/1
PEG needs positive PE and positive 5-year earnings growth.
Dividend Yield 1/2
Dividend yield (2.8%) is above the bottom 25% of dividend payers in the market.
Dividend Stability 1/2
Dividends paid without a cut of more than 10% for 8 years.
Dividend Growth 1/1
Dividends paid grew over the past 5 years.
Payout Ratio 0/1
Payout ratio is 160.6%, above 90% of earnings.
Each check is worth 1 or 2 points by how much it says about the quality of the company. The score is the share of points earned, out of 5. Ask AI to explain this score
Macrogen Inc stock price
Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.
About Macrogen Inc
Macrogen, Inc. provides genetic and genomic analysis research services in South Korea and internationally. It offers next generation sequencing (NGS) services, such as whole genome, exome, targeted, transcriptome, metagenome, epigenome, and single cell multi-omics sequencing, as well as whole genome resequencing; and standard, difficult template, and 16S/18S/26S rRNA and ITS region sequencing services, as well as animal/plant identification, PCR optimization/amplification, p…
Full company profileMacrogen Inc financial statements
2026 annualized: Fiscal year 2026 is not finished. Income statement and cash flow are annualized from 2 quarters up to Jun 30, 2026, the balance sheet is the latest quarter. Figures change when the annual report is published.
Macrogen Inc annual financial statements (KRW; K = thousand, M = million, B = billion, T = trillion)
| Item | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 Anlz |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Income Statement | |||||||||||
| Revenue | 91.1B | 102B | 113B | 122B | 113B | 129B | 139B | 133B | 136B | 195B | 193B |
| Gross Profit | 29.9B | 33.7B | 34.9B | 38.9B | 42.2B | 52.2B | 53.6B | 49.2B | 47.1B | 70.2B | 70.1B |
| Operating Income | 4.69B | 2.57B | 929M | 5.18B | 11.1B | 2.42B | -2.82B | -11.7B | -12.1B | 181M | 378M |
| EBITDA | - | - | - | - | - | - | -17.2B | -8.05B | 2.11B | 19.9B | 378M |
| Net Income | 4.30B | 9.53B | 2.65B | -3.50B | 88.3B | 1.11B | -22.3B | -16.8B | -7.60B | 2.03B | 8.92B |
| EPS | 484 | 1,047 | 264 | -355 | 9,053 | 112 | -2,216 | -1,685 | -701 | 187 | 823 |
| Balance Sheet | |||||||||||
| Total Assets | 160B | 179B | 180B | 226B | 288B | 301B | 280B | 258B | 330B | 352B | 370B |
| Total Liabilities | 77.0B | 84.4B | 61.5B | 112B | 89.6B | 101B | 101B | 98.6B | 152B | 179B | 199B |
| Shareholders' Equity | 82.6B | 94.3B | 118B | 113B | 198B | 201B | 179B | 159B | 161B | 157B | 156B |
| Cash & Short-term Investments | 59.1B | 83.6B | 82.3B | 56.0B | 57.1B | 60.8B | 47.9B | 25.3B | 42.6B | 47.5B | 56.4B |
| Total Debt | 9.20B | - | - | 38.1B | 31.5B | - | - | - | - | - | - |
| Cash Flow | |||||||||||
| Operating Cash Flow | 21.2B | 13.1B | 15.6B | 14.5B | 20.6B | 21.2B | 10.8B | 4.77B | 7.12B | 22.3B | 20.9B |
| Capital Expenditure | 14.9B | 11.2B | 7.22B | 62.5B | 18.4B | 9.59B | 19.8B | 24.3B | 35.5B | 36.0B | 24.2B |
| Free Cash Flow | - | - | - | - | 6.62B | 11.9B | -9.02B | -19.6B | -28.4B | -13.7B | -3.29B |
| Ratios | |||||||||||
| ROE | 5.2% | 10.1% | 2.2% | -3.1% | 44.6% | 0.6% | -12.4% | -10.6% | -4.7% | 1.3% | 5.7% |
| ROA | 2.7% | 5.3% | 1.5% | -1.6% | 30.7% | 0.4% | -7.9% | -6.5% | -2.3% | 0.6% | 2.4% |
| Net Profit Margin | 4.7% | 9.4% | 2.3% | -2.9% | 78.4% | 0.9% | -16.1% | -12.7% | -5.6% | 1.0% | 4.6% |
| Debt to Equity | 0.11x | - | - | 0.34x | 0.16x | - | - | - | - | - | - |
What these items mean
- Revenue
- Total sales of goods and services in the period.
- Gross Profit
- Revenue minus the direct cost of producing what was sold.
- Operating Income
- Profit from the core business after operating expenses.
- EBITDA
- Earnings before interest, taxes, depreciation and amortization.
- Net Income
- Profit left for shareholders after all expenses, interest and taxes.
- EPS
- Net income divided by shares outstanding.
- Total Assets
- Everything the company owns.
- Total Liabilities
- Everything the company owes.
- Shareholders' Equity
- Assets minus liabilities: the book value that belongs to shareholders.
- Cash & Short-term Investments
- Cash and investments that can be turned into cash quickly.
- Total Debt
- Short and long-term borrowings.
- Operating Cash Flow
- Cash generated by the core business.
- Capital Expenditure
- Cash spent on property, plant and equipment.
- Free Cash Flow
- Operating cash flow minus capital expenditure: cash left for dividends, buybacks or debt repayment.
- ROE
- Return on equity: net income divided by shareholders' equity.
- ROA
- Return on assets: net income divided by total assets.
- Net Profit Margin
- Net income as a share of revenue.
- Debt to Equity
- Total debt divided by shareholders' equity.
Macrogen Inc dividends
- Dividend yield
- 2.76%
- Forward dividend
- -
- Payout ratio
- 160.6%
- Ex-dividend date
- -
| Fiscal year | Dividends paid | Per share | Payout ratio |
|---|---|---|---|
| 2025 | KRW 3.26B | 301 | 160.6% |
| 2024 | KRW 2.99B | 276 | - |
| 2023 | KRW 3.01B | 302 | - |
| 2022 | KRW 2.96B | 295 | - |
| 2021 | KRW 2.93B | 296 | 263.3% |
| 2020 | KRW 2.93B | 300 | 3.3% |
| 2019 | KRW 2.93B | 297 | - |
| 2018 | KRW 2.93B | 292 | 110.7% |
| 2017 | - | - | - |
From the cash flow statement: dividends paid in the fiscal year, divided by that year's shares outstanding. Payout ratio = dividends paid / net income.
Last stock split: 3:2 on Mar 18, 2015.
Who owns Macrogen Inc
- Insiders 11.42%
- Institutions 6.10%
- Public & others 82.48%
- Shares outstanding 10.0M
- Free float 8.87M
Macrogen Inc company profile
- Company name
- Macrogen Inc
- Ticker
- 038290.KQ
- ISIN
- KR7038290003
- Exchange
- KOSDAQ
- Sector
- Healthcare
- Industry
- Life Sciences Tools & Services
- Employees
- 536
- Fiscal year end
- December
- Address
- 254, Beotkkot-ro, Seoul, South Korea
- Phone
- 82 2 2180 7000
- Website
- macrogen.com
About Macrogen Inc
Macrogen, Inc. provides genetic and genomic analysis research services in South Korea and internationally. It offers next generation sequencing (NGS) services, such as whole genome, exome, targeted, transcriptome, metagenome, epigenome, and single cell multi-omics sequencing, as well as whole genome resequencing; and standard, difficult template, and 16S/18S/26S rRNA and ITS region sequencing services, as well as animal/plant identification, PCR optimization/amplification, pyrosequencing, NGS validation, multi locus sequence typing analysis, sanger sequencing, primer walking, and cloning services. The company also provides fragment analysis services; clinical diagnostic; personal genome analysis; genetic testing services for research purposes, such as messenger RNA, microRNA, single nucleotide polymorphism, comparative genome hybridization, and DNA methylation; oligo and gene synthesis; and clustered regularly interspaced short palindromic repeats design and synthesis material, gRNA synthesis, validated gRNA, and gRNA plasmid services. In addition, it offers genetically engineered mice for use in biological and medical research to identify the functions of human genes; transgenic mouse in which a specific gene has been inserted to study the function of the gene; and GEM-related services, including mass reproduction, microinjection, mouse line recovery, embryo freezing and reproduction, and KO/TG mouse maintenance. Further, the company provides covid-19 test kit under the Axen name, as well as operates smart mobile lab for covid-19 testing. Additionally, it offers iD4U genetic testing services for kinship and personal identification; and myPETGENE genetic testing service for pets. Macrogen, Inc. was founded in 1997 and is headquartered in Seoul, South Korea.
Macrogen Inc management
1- Mr. Sukang LeeChief Exec. Officer · born 1966